Evidence for SGLT2 Drugs for Heart Failure in Patients without Diabetes | GameChangers
CEimpact Podcast
English - May 29, 2020 13:44 - 26 minutes - 17.9 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Hypercoagulability with COVID-19 infection | GameChangers
Geoff Wall, PharmD & Jamie Pitlick, PharmD discussing SGLT2 inhibitors, also called gliflozins, are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. Recently SGLTs, which are currently indicated for Type 2 diabetes, have been investigated and received FDA approval for Heart failure with reduced ejection fraction (HFrEF). Listen in to this episode to discover more about how these drugs work in this (HFrEF) disease state.This episode is accredited for CPE. This episode is accredited for CPE. For CE details and to claim credit click here: https://bit.ly/2ApMvWw See omnystudio.com/listener for privacy information.